quinazolines has been researched along with Bladder Cancer in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.27) | 18.7374 |
| 1990's | 7 (8.86) | 18.2507 |
| 2000's | 30 (37.97) | 29.6817 |
| 2010's | 37 (46.84) | 24.3611 |
| 2020's | 4 (5.06) | 2.80 |
| Authors | Studies |
|---|---|
| An, L; Chu, C; Li, L; Li, X; Liu, Q; Wang, R; Wang, Y; Wang, Z; Wei, X; Wu, G; Zhang, G | 1 |
| Bergum, N; Garrett, SH; Knutson, P; Mehus, AA; Sens, DA; Sens, MA; Shrestha, S; Somji, S; Zhou, XD | 1 |
| Chen, CT; Chen, JN; Cheng, L; He, YZ; Li, QY; Li, T; Liu, G; Qin, TS; Sun, YX; Wei, Y; Yao, D; Zhang, GJ | 1 |
| Cao, F; Gao, WB; Guo, XC; Pan, L; Zhang, YH; Zhu, HJ | 1 |
| Chin, CC; Huang, YC; Kuo, YH; Lee, YR; Li, JM; Shi, CS | 1 |
| Eriksson, P; Liedberg, F; Sjödahl, G | 1 |
| Ackerman, C; Gómez de Liaño, A; Powles, T | 1 |
| Cao, YP; Dong, Y; Huang, RM; Li, MQ; Sun, JY; Yan, J; Yan, X; Zhang, YH | 1 |
| Cronise, KE; Duval, DL; Gustafson, DL; Hernandez, BG | 1 |
| Aldousari, S; Chevalier, S; Kassouf, W; Mansure, JJ; Nassim, R; Rocha, J; Szymanski, K | 1 |
| Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ | 1 |
| Chang, C; Chen, CC; Chuang, WM; Hsieh, TF; Hung, XF; Lin, MH; Ma, WL; Shyr, CR; Tsai, YR; Zhang, C; Zhang, Q | 1 |
| He, D; Jin, X; Qu, S; Shi, Q; Zhang, T | 1 |
| Clozel, T; de Martino, M; Elemento, O; Klatte, T; Krzywinski, M; Rieken, M; Rouprêt, M; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| Altera, KP; Ames, MM; Buhrow, SA; Bunin, DI; Davis, M; Ji, J; Kinders, RJ; Lawrence, SM; Parman, T; Rausch, LL; Reid, JM; Samuelsson, SJ; Walden, C | 1 |
| He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Liu, WL; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Fenner, A | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Luo, Z; Nitin, N; Samadzadeh, KM | 1 |
| Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Choi, JH; Kim, JH; Kwak, Y; Lee, SH; Oh, CH; Roh, EJ; Sim, T; Song, C; Yoo, KH | 1 |
| Ackerman, C; Beresford, M; Berney, D; Chester, J; Chowdhury, S; Crabb, S; Elliott, T; Frew, JA; Hilman, S; Huddart, RA; Hughes, S; Hussain, S; Jagdev, S; Jones, R; Macdonald, G; Powles, T; Santhanam, S; Sarker, SJ; Stockdale, A | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Adam, L; Bar-Eli, M; Black, PC; Brown, GA; Dinney, CP; Fisher, MB; Gallagher, D; Inamoto, T; Kassouf, W; Luongo, T; McConkey, DJ | 1 |
| Bemis, LT; Flaig, TW; Li, Y; McCoach, C; Raben, D; Su, LJ; Varella-Garcia, M | 1 |
| Griffiths, TR; Kriajevska, M; Manson, MM; McHugh, LA; Mejlvang, J; Mellon, JK; Sayan, AE; Sun, Y; Tulchinsky, E | 1 |
| Allen, J; Bermingham, A; Boyer, B; Carragher, N; Costello, GF; Curwen, J; Davies, BR; Elvin, P; Fennell, M; Green, TP; Hargreaves, J; Hennequin, LF; Hickinson, DM; Holdgate, GA; Jacobs, V; Logie, A; Plé, PA; Ward, WH; Whittaker, R; Wilkinson, RW | 1 |
| Beuzeboc, P; De Groot, MR; El-Hariry, IA; Grimm, MO; Machiels, JP; Parikh, R; Pétavy, F; Richel, DJ; Treiber, U; Wülfing, C | 1 |
| Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD | 1 |
| Fielding, J; Godley, P; Grigson, G; Heathcote, S; Kim, W; Nielsen, M; Pruthi, RS; Rathmell, WK; Schultz, H; Smith, A; Wallen, EM; Whang, Y | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Arranz, EE; Auñón, PZ; Barón, MG; Marín, AP; Sánchez, AR | 1 |
| Flaig, TW; Li, Y; Su, LJ; Yang, X | 1 |
| Bode, AM; Grubbs, CJ; Juliana, MM; Lu, Y; Lubet, RA; Steele, VE; Townsend, R; Verney, ZM; You, M | 1 |
| Brierley, R | 1 |
| Boddy, AV; Heer, R; Karran, P; Newell, DR; O'Toole, K; Pridgeon, SW; Robinson, M; Taylor, GA; Xu, YZ | 1 |
| Grubbs, CJ; James, M; Liu, P; Lu, Y; Lubet, RA; Van den Bergh, F; Wen, W; You, M; Zellmer, V | 1 |
| Kim, JJ | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY; Yeh, CH | 1 |
| Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK; Symonds, RP | 1 |
| Lazarowicz, HP; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Davies, BR; Dominguez-Escrig, JL; Kelly, JD; King, SM; Neal, DE | 1 |
| Clarke, NW; Hendry, JH; Maddineni, SB; Margison, GP; Sangar, VK | 1 |
| Adam, L; Bar-Eli, M; Brown, G; Diehl, AJ; Dinney, CP; Kassouf, W; McConkey, DJ | 1 |
| Akaza, H; Hattori, K; Iida, K; Joraku, A; Oyasu, R; Tsukamoto, S | 1 |
| Adam, L; Brown, G; Dinney, CP; Kassouf, W; Luongo, T | 1 |
| Belldegrun, A; Figlin, R; Iwata, KK; Jin, Y; Lieberman, R; Pantuck, A; Rao, J; Zhang, ZF | 1 |
| Memon, AA; Munk, M; Nexo, E; Sorensen, BS | 1 |
| Memon, AA; Nexo, E; Sorensen, SB | 1 |
| Nexo, E; Ornskov, D; Sorensen, BS | 1 |
| Adam, L; Bar-Eli, M; Black, P; Brown, G; Dinney, CP; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Adam, L; Bar-Eli, M; Dinney, CP; Lashinger, L; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Foster, PA; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Brenner, PC; Goldstein, D; Hayes, VM; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Colquhoun, AJ; Kriajevska, M; Mchugh, LA; Mellon, JK; Tulchinsky, E | 1 |
| Baumgart, ED; Bernier, T; Cohen, MS; Jacobs, MA; Libertino, JA; Neto, BS; Rieger-Christ, KM; Summerhayes, IC; Wotkowicz, C | 1 |
| Erlichman, C; Hedley, DW; Mitrovski, B; Pressacco, J | 1 |
| Erlichman, C; Mandelbaum, S; Mitrovski, B; Pressacco, J | 1 |
| Erlichman, C; Mitrovski, B | 1 |
| Berthelemy, M; Dangles, V; Féménia, F; Lainé, V; Le Rhun, D; Levy, D; Poupon, MF; Schwartz-Cornil, I | 1 |
| Ariel, I; de-Groot, N; Elkin, M; Hochberg, A; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I | 1 |
| Aingorn, E; de-Groot, N; Elkin, M; Hochberg, A; Nagler, A; Pines, M; Reich, R; Vlodavsky, I | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Gildea, JJ; Gulding, KM; Harding, MA; Seraj, MJ; Theodorescu, D | 1 |
| Harris, AL; Streeter, EH | 1 |
| Kobayashi, S | 1 |
| Brunk, R; Engelbart, K; Schütz, E | 1 |
5 review(s) available for quinazolines and Bladder Cancer
| Article | Year |
|---|---|
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Role of anti-Her-2 therapy in bladder carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Models, Biological; Prognosis; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Urinary Bladder Neoplasms | 2010 |
Recent advances in treatment of advanced urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Doxorubicin; Female; Gefitinib; Humans; Immunotherapy; Male; Methotrexate; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quality Improvement; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Methotrexate; Muscle Neoplasms; Neoadjuvant Therapy; Oncogene Proteins v-erbB; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Cyclohexanes; DNA-Binding Proteins; Drug Combinations; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Nuclear Proteins; O-(Chloroacetylcarbamoyl)fumagillol; Piperidines; Quinazolines; Quinazolinones; Sesquiterpenes; Thymidine Phosphorylase; Transcription Factors; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
7 trial(s) available for quinazolines and Bladder Cancer
| Article | Year |
|---|---|
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Urinary Bladder Neoplasms | 2017 |
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Transitional Cell; Disease Progression; Female; Humans; Lapatinib; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Topics: Aged; Antineoplastic Agents; Cystectomy; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
67 other study(ies) available for quinazolines and Bladder Cancer
| Article | Year |
|---|---|
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Quinazolines; Urinary Bladder Neoplasms | 2023 |
Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
Topics: Animals; Arsenites; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Down-Regulation; ErbB Receptors; Hepatocyte Nuclear Factor 3-alpha; Humans; Keratins; Mice; Mice, Nude; PPAR gamma; Quinazolines; Transcription Factors; Transcriptome; Transplantation, Heterologous; Troglitazone; Up-Regulation; Urinary Bladder Neoplasms | 2020 |
Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Glutathione Peroxidase; Humans; Intracellular Space; Molecular Docking Simulation; Protein Conformation; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship; Urea; Urinary Bladder Neoplasms | 2020 |
Absolute Configurations and Chitinase Inhibitions of Quinazoline-Containing Diketopiperazines from the Marine-Derived Fungus
Topics: Cell Line, Tumor; Chitinases; Circular Dichroism; Diketopiperazines; Enzyme Inhibitors; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Penicillium; Prazosin; Quinazolines; Stomach Neoplasms; Urinary Bladder Neoplasms | 2020 |
Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinogenesis; Carcinoma; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fluorescein-5-isothiocyanate; Fluorouracil; Humans; Mutation; Plant Extracts; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms; Urothelium | 2017 |
Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Meta
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2017 |
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-lin
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Male; Mice, Nude; Quinazolines; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; HT29 Cells; Humans; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinazolines; Urinary Bladder Neoplasms; Vemurafenib | 2019 |
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Topics: Animals; Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; PPAR gamma; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms | 2014 |
Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.
Topics: Androgens; Animals; Butylhydroxybutylnitrosamine; Carcinogenesis; Castration; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Humans; Male; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Quinazolines; Receptors, Androgen; Signal Transduction; Transcriptional Activation; Urinary Bladder Neoplasms | 2013 |
Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Down-Regulation; Evodia; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2014 |
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2014 |
Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats.
Topics: Animals; Biomarkers, Tumor; Body Weight; Female; Glycosuria; Histones; Kidney Neoplasms; Male; Mesna; Phosphoproteins; Quinazolines; Random Allocation; Rats; Urinary Bladder Neoplasms | 2015 |
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, p53; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Bladder cancer: Patient-derived murine xenografts.
Topics: Animals; Female; Humans; Imidazoles; Male; MAP Kinase Signaling System; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms | 2015 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gefitinib; Humans; Optical Imaging; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Quinazolines; Urea; Urinary Bladder Neoplasms | 2016 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Topics: Analysis of Variance; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2008 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Piperidines; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2009 |
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Inhibitory Concentration 50; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clinical Trials, Phase II as Topic; Focal Adhesion Kinase 1; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; NIH 3T3 Cells; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Transplantation, Heterologous; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2009 |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quinazolines; Sensitivity and Specificity; Signal Transduction; Urinary Bladder Neoplasms | 2009 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Humans; Mesoderm; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Urinary Bladder Neoplasms; Vimentin | 2010 |
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Butylhydroxybutylnitrosamine; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Models, Biological; Quinazolines; Rats; Signal Transduction; Urinary Bladder Neoplasms | 2011 |
2011 ASCO Genitourinary Cancers Symposium.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2011 |
Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; DNA Damage; Female; Humans; Quinazolines; Radiation-Sensitizing Agents; Rats; Rats, Inbred F344; Thiophenes; Thymidine; Ultraviolet Therapy; Urinary Bladder Neoplasms | 2011 |
Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Urinary Bladder Neoplasms | 2012 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Breaks; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; ErbB Receptors; G1 Phase; Humans; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Random Allocation; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2013 |
Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
Topics: Antigens, Nuclear; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homologous Recombination; Humans; Imatinib Mesylate; Ku Autoantigen; Lapatinib; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Urinary Bladder Neoplasms | 2013 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
Topics: Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protease Inhibitors; Quinazolines; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Growth Processes; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Urinary Bladder Neoplasms | 2005 |
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cyclooxygenase Inhibitors; Gefitinib; Male; Meloxicam; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Thiazines; Thiazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Administration Schedule; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Quinazolines; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Topics: Actins; Anticarcinogenic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2006 |
Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; ErbB Receptors; Etoposide; Gefitinib; Humans; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Topics: Biomarkers; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Multigene Family; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Urinary Bladder Neoplasms | 2006 |
Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
Topics: Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Ligands; Quinazolines; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Urinary Bladder Neoplasms | 2006 |
Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; G1 Phase; Gefitinib; Humans; Mesoderm; Mice; Quinazolines; S Phase; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2007 |
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; X-Linked Inhibitor of Apoptosis Protein | 2007 |
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Early Growth Response Protein 1; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Topics: Analysis of Variance; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Interferon-alpha; Mutation; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2007 |
Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
Topics: Blotting, Western; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; STAT3 Transcription Factor; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2007 |
Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
Topics: Carrier Proteins; Humans; Indoles; Membrane Proteins; Nucleoside Transport Proteins; Quinazolines; Thiophenes; Thymidine Kinase; Thymidylate Synthase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Topics: Cell Survival; Deoxyuracil Nucleotides; Deoxyuridine; Folic Acid; Folic Acid Antagonists; Glutamates; Humans; In Vitro Techniques; Indoles; Isoindoles; Quinazolines; Structure-Activity Relationship; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1994 |
Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Drug Screening Assays, Antitumor; Fluorouracil; Folic Acid; Glutamates; Humans; Indoles; Isoindoles; Leucovorin; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1994 |
Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines.
Topics: Apoptosis; Culture Media, Serum-Free; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Epidermal Growth Factor; ErbB Receptors; Genistein; Humans; Isoflavones; Neoplasm Proteins; Nitriles; Protein-Tyrosine Kinases; Quinazolines; Spheroids, Cellular; Time Factors; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Urinary Bladder Neoplasms | 1997 |
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Topics: Animals; Antineoplastic Agents; Cell Division; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Stromal Cells; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Topics: Animals; Antineoplastic Agents; Carcinoma; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gelatin; Humans; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Neoplasm Transplantation; Piperidines; Promoter Regions, Genetic; Proteoglycans; Quinazolines; Quinazolinones; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
The role of Ral A in epidermal growth factor receptor-regulated cell motility.
Topics: Animals; Cell Movement; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Mice; Neoplasm Metastasis; Quinazolines; ral GTP-Binding Proteins; Tumor Cells, Cultured; Tyrphostins; Urinary Bladder Neoplasms | 2002 |
[Characterization and localization of alpha 1-adrenoceptors in human prostate--with special reference to the zonal difference in receptor distribution].
Topics: Autoradiography; Binding Sites; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha; Urinary Bladder Neoplasms | 1991 |
[Development of carcinoma of the urinary bladder in rats and dogs during oral administration of 1,2-dihydro-2-(5'-nitrofuryl)-4-hydroxy-chinazolin-3-oxide].
Topics: Animals; Carcinoma, Squamous Cell; Dogs; Female; Male; Metaplasia; Nitrofurans; Quinazolines; Rats; Time Factors; Urinary Bladder Neoplasms | 1973 |